---
layout: default
title: Amcinonide
description: "Amcinonide çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚ä¸­ç­‰è­‰æ“šç­‰ç´š L3ï¼ŒåŒ…å« 8 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 21
evidence_level: L3
indication_count: 8
---

# Amcinonide

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L3</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>8</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Amcinonideï¼šå¾ç•°ä½æ€§çš®è†šç‚åˆ°çš®è†šç‚

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Amcinonide å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Amcinonide åŸæœ¬ç”¨æ–¼æ²»ç™‚æ€¥æ…¢æ€§çš®è†šç—…å¦‚ç•°ä½æ€§çš®è†šç‚ã€æ¥è§¸æ€§çš®è†šç‚ã€ç‰›çš®ç™¬ç­‰ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**çš®è†šç‚ (dermatitis)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **20 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | ç•°ä½æ€§çš®è†šç‚ã€æ¥è§¸æ€§çš®è†šç‚ã€æ¿•ç–¹ã€ç‰›çš®ç™¬ã€ç¥ç¶“æ€§çš®è†šç‚ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | lichen diseaseã€seborrheic dermatitisã€seborrheic keratosisã€vulvar inverted follicular keratosisã€annular atrophic lichen planusã€lichen planus pigmentosusã€hypertrophic lichen planusã€primary cutaneous T-cell non-Hodgkin lymphoma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.30% |
| è­‰æ“šç­‰ç´š | L3 |
| å°ç£ä¸Šå¸‚ | æœ‰ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 6 å¼µï¼ˆå¤šæ•¸å·²è¨»éŠ·ï¼‰ |
| å»ºè­°æ±ºç­– | Already Approved (åŸé©æ‡‰ç—‡ç¯„åœå…§) |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. vulvar inverted follicular keratosis</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.82%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Amcinonide æ˜¯é«˜æ•ˆåƒ¹å±€éƒ¨é¡å›ºé†‡ï¼Œå±¬æ–¼å‰¯è…çš®è³ªè·çˆ¾è’™é¡è—¥ç‰©ã€‚å…¶ä½œç”¨æ©Ÿè½‰åŒ…æ‹¬ï¼š

1. **æŠ—ç™¼ç‚ä½œç”¨**ï¼šæŠ‘åˆ¶ç™¼ç‚ä»‹è³ªçš„é‡‹æ”¾ï¼Œæ¸›å°‘è¡€ç®¡æ“´å¼µèˆ‡æ°´è…«
2. **æŠ—éæ•ä½œç”¨**ï¼šç©©å®šè‚¥å¤§ç´°èƒï¼Œæ¸›å°‘çµ„ç¹”èƒºé‡‹æ”¾
3. **å…ç–«èª¿ç¯€**ï¼šæŠ‘åˆ¶å…ç–«ç´°èƒçš„æ´»åŒ–èˆ‡é·ç§»

é æ¸¬é©æ‡‰ç—‡ã€Œçš®è†šç‚ã€å¯¦éš›ä¸Šå·²åŒ…å«åœ¨åŸé©æ‡‰ç—‡ç¯„åœå…§ï¼ˆå¦‚ç•°ä½æ€§çš®è†šç‚ã€æ¥è§¸æ€§çš®è†šç‚çš†å±¬çš®è†šç‚ï¼‰ï¼Œæ­¤é æ¸¬å°è­‰äº†æ¨¡å‹å°è©²è—¥ç‰©é©æ‡‰ç—‡çš„æ­£ç¢ºè­˜åˆ¥ã€‚

### è‡¨åºŠè©¦é©—

ç›®å‰ç„¡é‡å° Amcinonide ç”¨æ–¼å»£æ³›çš®è†šç‚çš„æ–°è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [6383735](https://pubmed.ncbi.nlm.nih.gov/6383735/) | 1984 | RCT | Cutis | æ¯”è¼ƒ amcinonide èˆ‡ halcinonide æ²»ç™‚æ¿•ç–¹æ€§çš®è†šç‚ï¼Œå…©è€…å‡æœ‰æ•ˆ |
| [7030645](https://pubmed.ncbi.nlm.nih.gov/7030645/) | 1981 | RCT | Cutis | Amcinonide åœ¨ç·©è§£ç¼ç†±ç—›æ–¹é¢é¡¯è‘—å„ªæ–¼ halcinonide |
| [391500](https://pubmed.ncbi.nlm.nih.gov/391500/) | 1979 | RCT | Cutis | Amcinonide æ²»ç™‚æ¿•ç–¹æ€§çš®è†šç‚æ•ˆæœå„ªæ–¼ betamethasone valerate |
| [820519](https://pubmed.ncbi.nlm.nih.gov/820519/) | 1976 | CCT | Curr Ther Res | é›™ç›²æ¯”è¼ƒç ”ç©¶é¡¯ç¤º amcinonide èˆ‡ betamethasone valerate ç™‚æ•ˆç›¸ç•¶ |
| [32555122](https://pubmed.ncbi.nlm.nih.gov/32555122/) | 2020 | Review | Med Lett Drugs Ther | ç•°ä½æ€§çš®è†šç‚è—¥ç‰©ç¸½è¦½ï¼Œæ¶µè“‹ amcinonide ç­‰å±€éƒ¨é¡å›ºé†‡ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. annular atrophic lichen planus</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.73%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.73%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. lichen planus pigmentosus</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.73%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.73%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. hypertrophic lichen planus</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.73%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.73%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. lichen planus pemphigoides</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.64%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.64%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. primary cutaneous B-cell lymphoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.42%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.42%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. dermatitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.30%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.30%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. 2-hydroxyethyl methacrylate sensitization</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.00%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.00%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ | ç‹€æ…‹ |
|---------|------|------|-----------|------|
| è¡›ç½²è—¥è£½å­—ç¬¬027348è™Ÿ | é•·å®‰èˆ’æ·ä¹³è† | ä¹³è†åŠ‘ | çš®è†šç‚ã€æ¿•ç–¹ã€ç‰›çš®ç™¬ç­‰ | æœ‰æ•ˆ |
| è¡›ç½²è—¥è£½å­—ç¬¬023167è™Ÿ | è†šæ»‹ä¹³è† | ä¹³è†åŠ‘ | ç•°ä½æ€§çš®è†šç‚ã€æ¥è§¸æ€§çš®è†šç—… | å·²è¨»éŠ· |
| è¡›ç½²è—¥è£½å­—ç¬¬044950è™Ÿ | å®‰é©ä¹³è† | ä¹³è†åŠ‘ | æ€¥æ…¢æ€§çš®è†šç—… | å·²è¨»éŠ· |

å‚™è¨»ï¼šç›®å‰åƒ…ã€Œé•·å®‰èˆ’æ·ä¹³è†ã€è¨±å¯è­‰æœ‰æ•ˆï¼ˆè‡³2029å¹´ï¼‰ã€‚

## å®‰å…¨æ€§è€ƒé‡

- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼š
  - **è¼•å¾®äº¤äº’ä½œç”¨**ï¼šèˆ‡å¤šç¨®é™è¡€ç³–è—¥ç‰©ï¼ˆMetforminã€Glimepirideã€å„é¡èƒ°å³¶ç´ ç­‰ï¼‰ä½µç”¨å¯èƒ½å½±éŸ¿è¡€ç³–æ§åˆ¶
- **å±€éƒ¨ä½¿ç”¨æ³¨æ„äº‹é …**ï¼š
  - é•·æœŸä½¿ç”¨å¯èƒ½å°è‡´çš®è†šèç¸®ã€æ¯›ç´°è¡€ç®¡æ“´å¼µ
  - å¤§é¢ç©æˆ–å°é–‰å¼ä½¿ç”¨å¯èƒ½å¢åŠ å…¨èº«æ€§å¸æ”¶é¢¨éšª
- **éæ•åæ‡‰**ï¼šæ–‡ç»å ±å‘Šé¡¯ç¤ºéƒ¨åˆ†æ‚£è€…å° amcinonide ç”¢ç”Ÿæ¥è§¸æ€§çš®è†šç‚ï¼Œéœ€æ³¨æ„äº¤å‰éæ•


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**ç³–å°¿ç—… (Diabetes Mellitus)** ğŸŸ¡ Moderate
- Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely pr...

**Diaper Rash** ğŸŸ¡ Moderate
- Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absor...

**Adrenocortical Hyperfunction** ğŸŸ¡ Moderate
- The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehi...

**Infections** ğŸŸ¡ Moderate
- Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically signif...

**Toxic Optic Neuropathy** ğŸŸ¡ Moderate
- Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effe...

*å¦æœ‰ 5 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šAlready Approved (åŸé©æ‡‰ç—‡ç¯„åœå…§)**

**ç†ç”±ï¼š**
é æ¸¬é©æ‡‰ç—‡ã€Œçš®è†šç‚ã€å¯¦éš›ä¸Šå·²åŒ…å«åœ¨åŸæ ¸å‡†é©æ‡‰ç—‡ä¸­ã€‚Amcinonide ä½œç‚ºé«˜æ•ˆåƒ¹å±€éƒ¨é¡å›ºé†‡ï¼Œå°å„é¡çš®è†šç‚å‡æœ‰ç™‚æ•ˆã€‚æ­¤é æ¸¬é©—è­‰äº†æ¨¡å‹å°è—¥ç‰©-ç–¾ç—…é—œä¿‚çš„æ­£ç¢ºè­˜åˆ¥ã€‚

**è‡¨åºŠå»ºè­°ï¼š**
- ä¾æ“šçš®è†šç‚åš´é‡ç¨‹åº¦é¸æ“‡é©ç•¶æ•ˆåƒ¹çš„é¡å›ºé†‡
- æ³¨æ„ä½¿ç”¨éƒ¨ä½ï¼ˆè‡‰éƒ¨ã€çšºè¤¶è™•æ‡‰é¿å…ä½¿ç”¨é«˜æ•ˆåƒ¹é¡å›ºé†‡ï¼‰
- ç›£æ¸¬é•·æœŸä½¿ç”¨çš„å±€éƒ¨å‰¯ä½œç”¨


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Durvalumab]({{ "/drugs/durvalumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Human Immunoglobulin G]({{ "/drugs/human_immunoglobulin_g/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Alfacalcidol]({{ "/drugs/alfacalcidol/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Acitretin]({{ "/drugs/acitretin/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Interferon Beta-1B]({{ "/drugs/interferon_beta-1b/" | relative_url }}) - è­‰æ“šç­‰ç´š L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Amcinonideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/amcinonide/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_amcinonide,
  title = {Amcinonideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/amcinonide/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
